Recent Updates
Recently added Catalysts
NBIX Positive Sentiment

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

Tuesday, March 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Neurocrine Biosciences has promoted Andrew Ratz, Ph.D., to Chief Technical Operations Officer. In this role, he will oversee global technical development, manufacturing, and supply chain functions. This strategic move aligns with the company's goal to expand its portfolio beyond small molecules into biologics and device-based therapies.
Price reaction · baseline $129.85 (2026-03-16 close) · hit after-hours · clean, no other NBIX news in the window
day 0 close · peak
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Andrew Ratz's promotion reflects the company's commitment to leadership.
  • The appointment supports Neurocrine's expansion into biologics and device-based therapies.
  • Dr. Ratz brings valuable experience to the executive management team.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
3.5%
average across 4 past catalysts
Lead asset
NBI-6024
Phase 1 · Type 1 Diabetes Mellitus

Full Press Release Details

SAN DIEGO,March 17, 2026/PRNewswire/ --Neurocrine Biosciences, Inc.(Nasdaq:NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr. Ratz will lead the company's global technical development, manufacturing, and supply chain functions, supporting Neurocrine's expansion beyond small molecules into biologics and device-based therapies.

Frequently Asked Questions

Who has been appointed as the new CTO of Neurocrine Biosciences?

Andrew Ratz, Ph.D., has been promoted to Chief Technical Operations Officer.

What will Andrew Ratz oversee in his new role?

He will lead global technical development, manufacturing, and supply chain functions.

What is Neurocrine's focus with this appointment?

The company aims to expand beyond small molecules into biologics and device-based therapies.

When was the announcement made?

The announcement was made on March 17, 2026.

ShareAdd on Google
Tags: NBIX Viatris Investor Conferences Healthcare Neurocrine Biosciences Andrew Ratz Chief Technical Operations Officer biologics device-based therapies
Last updated: Mar 17, 2026

Biotech snapshot

Cash runway
$482M liquidity · $0M/mo burn
Low dilution risk
Lead asset
NBI-6024Phase 1
Type 1 Diabetes Mellitus →

Catalyst track record

+37%
best trade around NBIX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NBIX.

See every catalyst's timing & PoA →